Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer

Kawano, Yoshifumi; Lee, Chan Lee; Watanabe, Tsutomu; Abe, Takanori; Suzuya, Hiroko; Okamoto, Yasuhiro; Makimoto, Atsushi; Nakagawa, Ryuji; Watanabe, Hiroyoshi; Takaue, Yoichi
January 2004
Annals of Hematology;Jan2004, Vol. 83 Issue 1, p50
Academic Journal
Cryopreservation of peripheral blood stem cells (PBSC) mobilized by chemotherapy combined with or without granulocyte colony-stimulating factor (G-CSF) is an essential part of procedure for anti-cancer strategies. We evaluated whether a higher cell concentration (2×108/ml) without the use of a programmed freezer was acceptable for the storage of mobilized PBSC in an autologous setting. Mobilized PBSC were enriched to mononuclear cells (MNC) by Percoll separation and then frozen at cell concentrations of 2–5×107/ml (group I, n=20) or 2×108/ml (group II, n=44) without the use of a programmed freezer using 5% DMSO, 6% hydroxy ethyl starch, and 4% autologous serum or human albumin. CD34+ cells purified by ISOLEX300 were frozen at 2×107/ml (group III, n=22) using the same method. The median recovery rates of CD34+ cells and CFU-GM were, respectively, n.d. (not determined) and 88% in group I, 103 and 64% in group II, and 98 and 53% in group III. There was a statistical significance between the recovery rate of CFU-GM in group III and that in group I (p=0.02). The median percentage of cell viability after thawing in each group was 89, 87, and 75%, respectively. The median numbers of days after PBSCT to achieve a WBC of >1.0×109/l, an absolute neutrophil count of >0.5×109/l, and a platelet count of >50×109/l were, respectively, 11, 11 and 15 in group I; 12, 12 and 16 in group II; and 12, 12 and 27 in group III. These results suggest that enriched MNC from mobilized PBSC could be frozen at a higher cell concentration (2×108/ml) without the use of a programmed freezer, leading to reduction of the toxicities associated with infusion of thawed cells and of costly space required for cell storage.


Related Articles

  • Leucocyte common antigen (CD45) and CD5 positivity in an "undifferentiated" carcinoma: a potential diagnostic pitfall. Nyethane Ngo; Patel, Kaushik; Isaacson, Peter G.; Naresh, Kikkeri N. // Journal of Clinical Pathology;Aug2007, Vol. 60 Issue 8, p936 

    The article presents the case of a patient who had leucocyte common antigen- (CD45) and CD5-expressing carcinoma and bilateral cervical lymphadenopathy. Based on blood test results, the patient had low albumin, abnormal liver function and normal blood counts, serum calcium, cholesterol and...

  • Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. Schappa, Jill T.; Frantz, Aric M.; Gorden, Brandi H.; Dickerson, Erin B.; Vallera, Daniel A.; Modiano, Jaime F. // BMC Proceedings;2013, Vol. 7 Issue Suppl 2, p1 

    The article presents information on a study related to the impact of a toxin targeted through epidermal growth factor and urokinase receptors on hemangiosarcoma and its cancer stem cell subpopulation. The method includes evaluation of EGFuPA-toxin activity in four human serum albumin (HSA) cell...

  • Controversies in cancer stem cells. Jones, Richard J. // Journal of Molecular Medicine;Nov2009, Vol. 87 Issue 11, p1077 

    The article discusses various reports related to cancer stem cells published within the issue, including "Cancer Stem Cells: Controversies in Multiple Myeloma," by Sarah Brennan and William Matsui, "Brain Cancer Stem Cells," by Angelo Vescovi, and "Colon Cancer Stem Cells," by Ruggero De Maria.

  • Stem cells: Cancer stem cells on demand. Nawy, Tal // Nature Methods;Jul2014, Vol. 11 Issue 7, p715 

    The article focuses on the findings of a study conducted by Bradley Bernstein of Harvard Medical School and colleagues on the induction of a stem cell state by expressing four factors in glioblastoma cells.

  • Erratum.  // JNCI: Journal of the National Cancer Institute;Aug2012, Vol. 104 Issue 15, p1123 

    A correction to the article "Cancer Stem Cells: Cancer's Roots," by Anna Azvolinsky, published in the 2012 issue, is presented.

  • Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bewick, M; Chadderton, T; Conlon, M; Lafrenie, R; Morris, D; Stewart, D; Glück, S // Bone Marrow Transplantation;8/15/99, Vol. 24 Issue 4, p377 

    C-erbB-2/HER-2 (designated HER-2) is overexpressed in both primary and metastatic breast cancer and predicts poor prognosis. We investigated the expression of HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy (HDCT) with autologous blood stem cell (ABSC) support...

  • Anti-DLL4, a cancer therapeutic with multiple mechanisms of action.  // Vascular Cell;May2011, Vol. 3, p18 

    A review of the article "Anti-DLL4, a cancer therapeutic with multiple mechanisms of action," by Austin Gurney and Timothy Hoey, published in a 2011 issue, is presented.

  • A new red line.  // Discover;Nov99, Vol. 20 Issue 11, p40 

    Reports on researches on the regeneration of stem cells for cancer patients who undergo chemotherapy.

  • Stem cells, cancer, and cancer stem cells. Reya, Tannishtha; Morrison, Sean J.; Clarke, Michael F.; Weissman, Irving L. // Nature;11/1/2001, Vol. 414 Issue 6859, p105 

    Discusses evidences that stem cell biology could provide insights into cancer biology. Similarities in the mechanisms that regulate self-renewal of normal stem cells and cancer cells; Possibility that tumor cells developed from normal stem cells.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics